BR112022015858A2 - Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose - Google Patents
Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometrioseInfo
- Publication number
- BR112022015858A2 BR112022015858A2 BR112022015858A BR112022015858A BR112022015858A2 BR 112022015858 A2 BR112022015858 A2 BR 112022015858A2 BR 112022015858 A BR112022015858 A BR 112022015858A BR 112022015858 A BR112022015858 A BR 112022015858A BR 112022015858 A2 BR112022015858 A2 BR 112022015858A2
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- endometriosis
- pain
- disorder
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Burglar Alarm Systems (AREA)
- Amplifiers (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977008P | 2020-02-14 | 2020-02-14 | |
| PCT/IB2021/000091 WO2021161105A1 (en) | 2020-02-14 | 2021-02-12 | P2x3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015858A2 true BR112022015858A2 (pt) | 2022-10-25 |
Family
ID=77292083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015858A BR112022015858A2 (pt) | 2020-02-14 | 2021-02-12 | Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312557A1 (https=) |
| EP (1) | EP4103564A4 (https=) |
| JP (1) | JP2023513373A (https=) |
| KR (1) | KR20220141331A (https=) |
| CN (2) | CN119039290A (https=) |
| AU (1) | AU2021219097A1 (https=) |
| BR (1) | BR112022015858A2 (https=) |
| CA (1) | CA3170664A1 (https=) |
| IL (1) | IL295393A (https=) |
| MX (1) | MX2022009762A (https=) |
| WO (1) | WO2021161105A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7578602B2 (ja) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| CN115427419B (zh) * | 2020-02-14 | 2026-04-21 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | P2x3拮抗剂的制备 |
| WO2021244634A1 (zh) * | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| WO2022156783A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| CN115043836B (zh) * | 2021-08-20 | 2023-07-18 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN03391A (https=) * | 2009-11-18 | 2015-10-23 | Astrazeneca Ab | |
| DK3381917T3 (da) * | 2013-01-31 | 2021-10-18 | Bellus Health Cough Inc | Imidazopyridinforbindelser og anvendelser deraf |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| KR102797127B1 (ko) * | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| JP7578602B2 (ja) * | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
-
2021
- 2021-02-12 EP EP21754440.2A patent/EP4103564A4/en active Pending
- 2021-02-12 JP JP2022548875A patent/JP2023513373A/ja not_active Ceased
- 2021-02-12 AU AU2021219097A patent/AU2021219097A1/en not_active Abandoned
- 2021-02-12 CA CA3170664A patent/CA3170664A1/en active Pending
- 2021-02-12 KR KR1020227031507A patent/KR20220141331A/ko active Pending
- 2021-02-12 CN CN202411099037.4A patent/CN119039290A/zh active Pending
- 2021-02-12 MX MX2022009762A patent/MX2022009762A/es unknown
- 2021-02-12 WO PCT/IB2021/000091 patent/WO2021161105A1/en not_active Ceased
- 2021-02-12 CN CN202180028882.0A patent/CN115413279A/zh active Pending
- 2021-02-12 BR BR112022015858A patent/BR112022015858A2/pt not_active IP Right Cessation
- 2021-02-12 IL IL295393A patent/IL295393A/en unknown
- 2021-02-12 US US17/929,035 patent/US20230312557A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170664A1 (en) | 2021-08-19 |
| AU2021219097A1 (en) | 2022-09-01 |
| US20230312557A1 (en) | 2023-10-05 |
| EP4103564A1 (en) | 2022-12-21 |
| KR20220141331A (ko) | 2022-10-19 |
| EP4103564A4 (en) | 2024-05-01 |
| MX2022009762A (es) | 2022-09-09 |
| IL295393A (en) | 2022-10-01 |
| JP2023513373A (ja) | 2023-03-30 |
| WO2021161105A1 (en) | 2021-08-19 |
| CN119039290A (zh) | 2024-11-29 |
| CN115413279A (zh) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015858A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| BR112022014968A2 (pt) | Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112014016672A2 (pt) | compostos de carbamato e sua preparação e uso | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| ECSP088762A (es) | Tratamiento del dolor | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| BRPI0812504B8 (pt) | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero | |
| EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| BR112021006398A2 (pt) | tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| CL2008002384A1 (es) | Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
| PH12022552447A1 (en) | Nlrp3 modulators | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: BELLUS HEALTH INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: 14245563 CANADA INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED (GB) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2866 DE 09/12/2025. |